78 results on '"Polliack A"'
Search Results
2. Efficacy of a third BNT162b2 mRNA COVID-19 vaccine dose in patients with CLL who failed standard 2-dose vaccination
3. Primary peg-filgrastim prophylaxis versus filgrastim given “on demand” for neutropenia during therapy with cladribine for hairy cell leukemia
4. Systemic lupus erythematosus and lymphoma: Incidence, pathogenesis and biology
5. Hodgkin lymphoma of the gastrointestinal tract in patients with inflammatory bowel disease: Portrait of a rare clinical entity
6. Primary plasma cell leukemia in the era of novel agents for myeloma – a multicenter retrospective analysis of outcome
7. The Clinical Spectrum of Hepatic Manifestations in Chronic Lymphocytic Leukemia
8. Nodal marginal zone lymphoma: Clinical features, diagnosis, management and treatment
9. Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia
10. Autoimmune hemolytic anemia (AIHA) associated with chronic lymphocytic leukemia in the current era of targeted therapy
11. Discordant bone marrow involvement in non-Hodgkin lymphoma
12. Hairy cell leukemia: Uncommon clinical features, unusual sites of involvement and some rare associations
13. Epidemiology and environmental risk in hairy cell leukemia
14. Integration of automated morphological features resolves a distinct group of atypical chronic lymphocytic leukemias with chromosomal aberrations
15. Advising Patients on the Use of Non-Herbal Nutritional Supplements During Cancer Therapy: A Need for Doctor-Patient Communication
16. Monocytosis has adverse prognostic significance and impacts survival in patients with T-cell lymphomas
17. Predictive Parameters for a Diagnostic Bone Marrow Biopsy Specimen in the Work-Up of Fever of Unknown Origin
18. Optimal management of older patients with chronic lymphocytic leukemia: Some facts and principles guiding therapeutic choices
19. Merkel cell carcinoma, chronic lymphocytic leukemia and other lymphoproliferative disorders: an old bond with possible new viral ties
20. Two cycles of escalated BEACOPP followed by four cycles of ABVD utilizing early-interim PET/CT scan is an effective regimen for advanced high-risk Hodgkin's lymphoma
21. Cell of origin (COO), BCL2/MYC status and IPI define a group of patients with Diffuse Large B-cell Lymphoma (DLBCL) with poor prognosis in a real-world clinical setting
22. Posttraumatic stress disorder, tenderness, and fibromyalgia syndrome: are they different entities?
23. A New Technology for Reducing Shear and Friction Forces on the Skin: Implications for Blister Care in the Wilderness Setting
24. Is CT scan still necessary for staging in Hodgkin and non-Hodgkin lymphoma patients in the PET/CT era?
25. Preauthorization of CT and MRI Examinations: Assessment of a Managed Care Preauthorization Program Based on the ACR Appropriateness Criteria ® and the Royal College of Radiology Guidelines
26. Chronic lymphocytic leukemia: A review of some new aspects of the biology, factors influencing prognosis and therapeutic options
27. The Involvement of LAG3+ Plasma Cells in the Development of Multiple Myeloma
28. The Integration of Efficacy and Safety Outcomes Identifies the Net Clinical Benefit of Targeted Agents in Upfront Therapy of Chronic Lymphocytic Leukemia: Results of Network Meta-Analysis
29. ABL1 Methylation Is a Distinct Molecular Event Associated With Clonal Evolution of Chronic Myeloid Leukemia
30. External Validation of a Novel Risk Model (BALL Score) in Real-World Relapsed/Refractory Chronic Lymphocytic Leukemia Patients Receiving Ibrutinib. a Campus CLL Study
31. Shiga-like Toxin Producing E. coli Identified in Patients with Multiple Myeloma (MM) Hospitalized Due to Acute Onset Diarrhea; First Report on the Clinical Use of the Biofire Film Array Gastrointestinal Panel
32. Clomiphene as a novel modality for the treatment of acute myeloid leukemia: A pilot phase II study
33. Marginal zone lymphomas: Reconsidering similarities and differences while moving towards personalized treatment
34. Phase 3 Study of Ibrutinib versus Chlorambucil in Patients ≥65 Years with Treatment-Naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
35. Neutrophil - Lymphocyte Ratio (NLR) at Diagnosis Is an Independent Prognostic Factor in Patients with Nodular Sclerosis Hodgkin Lymphoma: Results of a Large Multicenter Study Involving 990 Patients
36. Neutrophil to Lymphocyte Ratio at Diagnosis Is an Independent Prognostic Factor in Diffuse Large B-Cell Lymphoma: Results of a Large Multicenter Study Involving 931 Patients
37. Results from the International, Randomized Phase 3 Study of Ibrutinib Versus Chlorambucil in Patients 65 Years and Older with Treatment-Naïve CLL/SLL (RESONATE-2TM)
38. Efficacy and Safety of Frontline Therapy with "FCR" Regimen for Chronic Lymphocytic Leukemia Outside Clinical Trials: Israeli CLL Study Group Experience
39. Cancer Registries Often Underestimate the True Incidence of CLL
40. Risk of Second Malignancies after Non Hodgkin Lymphoma: A Cohort Study of 22,466 Survivors in Israel
41. High Risk Advanced Stage Hodgkin Lymphoma Is Well Controlled with 2 Cycles of Escalated Beacopp Followed By 4 Cycles of ABVD in Patients Who Rapidly Achieve Metabolic CR on Interim PET/CT Scan
42. Increased CD39 Expression on CD4+ T-Lymphocytes Has Clinical and Prognostic Significance in Chronic Lymphocytic Leukemia,
43. Absolute Monocytosis At Diagnosis Is Associated with Poor Survival in Diffuse Large B-Cell Lymphoma -Possibly Related to Increase in Monocytic-Myeloid Derived Suppressor Cells
44. Immunochemotherapy with Low-Dose Subcutaneous Alemtuzumab (A) Plus Oral Fludarabine and Cyclophosphamide (FC) Is Safe and Induces More and Deeper Complete Remissions in Untreated Patients with High-Risk Chronic Lymphocytic Leukemia (CLL) Than Chemotherapy with FC Alone. An Early Analysis of the Randomized Phase-III HOVON68 CLL Trial
45. 3.16 Increased Incidence of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma in Patients with Merkel Cell Carcinoma in Israel
46. 2.7 Intra-Clonal Diversity Identified by CD19-Mediated Signaling Correlates with Disease Progression in CLL
47. PO10-TU-55 The use of a walking cane: attitudes and preferences of patients with multiple sclerosis
48. Fred Astren Karaite Judaism and Historical Understanding 2004 University of South Carolina Press Columbia, SC 360 pp., $49.95 (hardback), ISBN 1 57003 518 0
49. Combined escBEACOPP-ABVD Therapy for Advanced Hodgkin's Lymphoma Patients with High IPS Score: An Effective Regimen and Low Positive Predictive Value of Early FDG-PET/CT Scan.
50. Chromosomal Abnormalities Detected by FISH in CLL May Be Influenced by Ethnic Origin: Preliminary Data from a Multicenter Study in Israel for the Israel CLL Study Group (ICLLSG).
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.